Experience

Intezyne Technologies

• United States
• Biotechnology
• 1 - 100 Employee

• Senior Scientist

  • Jun 2011 - Feb 2016

  Proposed and synthesized polymers for targeted drug delivery. Invented API manufacture process for IT-139 (BOLD-100) and optimized it on a pilot scale, transferred the technology to a GMP partner. Developed new methods for preparation of heterofunctionalized PEGs, by EO anionic polymerization on a kilo scale Proposed and synthesized polymers for targeted drug delivery. Invented API manufacture process for IT-139 (BOLD-100) and optimized it on a pilot scale, transferred the technology to a GMP partner. Developed new methods for preparation of heterofunctionalized PEGs, by EO anionic polymerization on a kilo scale



Johns Hopkins University

• United States
• Hospitals and Health Care
• 1 - 100 Employee

• research specialist

  • May 2010 - Jan 2011

  SAR optimization of neuroprotective kinase inhibitors, for treatment of glaucoma SAR optimization of neuroprotective kinase inhibitors, for treatment of glaucoma



The Scripps Research Institute - Florida campus

• sr. associate scientist

  • Jun 2004 - Dec 2009

  SAR-optimization of kinase inhibitors for treatment of neurodegeneration, cancer, glaucoma and inflammation (ROCK, Jnk, VEGF + PDGF, p38, Src projects). Process methodology development and scale up of key building blocks SAR-optimization of kinase inhibitors for treatment of neurodegeneration, cancer, glaucoma and inflammation (ROCK, Jnk, VEGF + PDGF, p38, Src projects). Process methodology development and scale up of key building blocks



Celera Genomics

• sr. associate

  • Sep 2003 - Apr 2004

  A late-stage optimization of factor VIIa parenteral anticoagulants: Synthesis and selection of a preclinical candidate and its scale-up, a process route optimization A late-stage optimization of factor VIIa parenteral anticoagulants: Synthesis and selection of a preclinical candidate and its scale-up, a process route optimization



Pharmacia/Pfizer

• sr. associate

  • Sep 2000 - Aug 2003

  Development of SU 14813 (currently a phase II Sutent follow up with improved PK properties). Discovery of a novel class of highly selective low-nM low-molecular weight inhibitors of c-Met kinase. Development of SU 14813 (currently a phase II Sutent follow up with improved PK properties). Discovery of a novel class of highly selective low-nM low-molecular weight inhibitors of c-Met kinase.



Sanofi-Aventis

• France
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• associate chemist

  • Dec 1993 - May 1997

  Application of organic reactions in parallel synthesis - Discovery of novel acyliminium tandem cyclizations on solid phase Application of organic reactions in parallel synthesis - Discovery of novel acyliminium tandem cyclizations on solid phase



Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic

• Czechia
• Research Services
• 300 - 400 Employee

• research assistant

  • Oct 1992 - Nov 1993

  Solid-phase synthesis, peptide phosphorylation, combinatorial chemistry methodology Solid-phase synthesis, peptide phosphorylation, combinatorial chemistry methodology